PASG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
PASG is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has no proprietary buy signal, the technical setup is still bearish, and the latest analyst moves were mostly downgrades with sharply lower targets after the FDA required a more difficult registrational study. There is upside potential if the company can secure funding or a strategic alternative creates value, but based on the current data I would not buy it now.
The current trend is weak. MACD histogram is negative at -0.0849 and still below zero, RSI_6 at 38 suggests the stock is not oversold enough to signal a strong rebound, and the moving averages remain bearish with SMA_200 > SMA_20 > SMA_5. Price at 4.625 is below the pivot of 4.908, which also indicates lack of near-term momentum. Support sits at 3.758 and 3.047, while resistance is 6.057 and 6.768. The short-term pattern data is mixed to mildly negative, with a weak next-week expectation.
["Updated upliFT-D clinical data showed encouraging signals across brain imaging, biomarkers, and safety.", "Oppenheimer noted that the dataset supports continued exploration of PBFT02, especially in milder patients.", "The company is exploring strategic alternatives to maximize shareholder value, which could create a corporate catalyst if a transaction emerges."]
["FDA feedback requires a randomized, placebo-controlled registrational study for PBFT02, removing the easier approval path.", "Multiple analysts downgraded the stock and cut price targets sharply after the regulatory update.", "Funding the required registrational study adds significant operational and financial burden.", "No recent insider buying, no meaningful hedge fund accumulation, and no recent congress trading support.", "No AI Stock Picker or SwingMax signal is present today."]
No usable financial snapshot was provided, so latest-quarter revenue or cash trend cannot be confirmed. From the available qualitative data, the key financial concern is not operating growth but the ability to fund the next development stage after the FDA required a larger randomized study. This makes the latest quarter less important than the company’s financing capacity and runway.
Recent analyst trend is clearly negative. Wedbush downgraded PASG to Neutral from Outperform and cut the target to $8 from $32. TD Cowen downgraded to Hold from Buy with no target. Chardan downgraded to Neutral from Buy with a $7 target. Lucid Capital also downgraded to Neutral with a $9 target. Oppenheimer was the most constructive, keeping Outperform but cutting the target to $15 from $30. Overall Wall Street view is cautious to bearish: the positive side is that the data may still support the program, but the negative side is that FDA guidance makes approval and financing much harder.
